The MACHT (Midodrine and Albumin for Cirrhotic patients in the waiting list for liver Transplantation) study, a multicenter, randomized, double blinded placebo‐controlled trial, also explored the effects of long‐term infusion of HA (40 g every 15 days) in 196 patients, of whom 99 received HA, with cirrhosis and ascites while waitlisted for liver transplantation.20 The gene discussed is ALB; the disease is Cirrhosis.